A clinical trial led and coordinated by Hospital Cl?nic-IDIBAPS, using a drug named Sorafenib, revolutionizes the reality of patients suffering from advanced liver cancer. The results increase overall survival of treated patients by 44 percent in comparison to the control group. The results have been hand selected to be included on the “Best of ASCO” program.
Bayer HealthCare, a subsidiary of Bayer AG (NYSE: BAY), and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar? (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%.
GlaxoSmithKline (NYSE: GSK) announced that the European Commission approved its novel topical antibacterial ALTARGO? (retapamulin ointment,1%) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds.
In the first scientific study of its kind, shark cartilage extract, AE-941 or neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, researchers say.
North Central Cancer Treatment Group researchers based at Mayo Clinic in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.
A drug described by some people as a “genius pill” for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as “chemo-brain,” according to a University of Rochester Medical Center study.
North Central Cancer Treatment Group researchers, based at Mayo Clinic in Rochester, Minn., have generated preliminary data suggesting that a form of American ginseng provides greater improvements in fatigue and vitality in patients who receive the highest doses tested, compared to lower doses or no treatment.
In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at the University of Texas M. D. Anderson Cancer Center.
Oregon Health & Science University Cancer Institute researchers have identified a protein that is a strong indicator of survival for men with advanced prostate cancer.
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; Accentia) reports that the Mayo Medical and Graduate Schools and the Virginia Bioinformatics Institute have been awarded a National Institute of Health (NIH) grant of $2.4 million for a project entitled “The Pathogenesis of Chronic Rhinosinusitis.”